Hexahydrocurcumin

Hexahydrocurcumin (HHC), classified as a linear diarylheptanoid, serves as a potent and selective COX-2 inhibitor. It is a natural glucuronide metabolite derived from curcumin, a well-known natural compound found in both the rhizome of Curcuma longa, commonly known as turmeric, and Zingiber officinale, or ginger. This compound distinguishes itself with exceptional stability and enhanced bioavailability in comparison to curcumin, offering an array of therapeutic attributes, including anti-inflammatory, anticancer, antioxidant, and neuroprotective properties. HHC has also demonstrated its therapeutic potential by reducing prostaglandin E2 (PGE2) production and inhibiting nitric oxide overproduction, paving the way for its use in combating a range of health concerns, from colon cancer to inflammatory responses. Additionally, HHC is also recognized for its role in preventing the formation of aberrant crypt foci in a dimethylhydrazine rat model of colon cancer and enhancing the efficacy of 5-fluorouracil

Hexahydrocurcumin finds application in metabolomic research for investigating a wide range of health benefits, primarily encompassing its roles in managing oxidative stress, cancer, inflammation, and various other health conditions.

In vitro, hexahydrocurcumin (HHC) exhibited a marked decrease in the viability of HT-29 human colon cancer cells compared to the control. HHC also significantly down-regulated COX-2 mRNA expression (control: 100.05% ± 0.03% vs HHC: 61.01% ± 0.35%, P < 0.05) without affecting COX-1 mRNA. Notably, when HHC was added to a low dose of 5-Fluorouracil in combined treatment, it exerted a synergistic effect against the growth of HT-29 cells, leading to a more substantial reduction in cell viability compared to monotherapy

For additional information on our range of Biochemicals, please complete this form.

This product is intended for research purposes only, and it is not meant for human consumption.